Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maltitol SCHEMBL18744689 | 1.00 | L3MBTL1 (0.41) | L3MBTL1PPARGPPARDPPARAMEN1 | |
| Maltitol SCHEMBL8600577 | 1.00 | L3MBTL1 (0.41) | L3MBTL1PPARGPPARDPPARAMEN1 | |
| Maltitol SCHEMBL7149629 | 1.00 | L3MBTL1 (0.41) | L3MBTL1PPARGPPARDPPARAMEN1 | |
| Maltitol SCHEMBL13024834 | 1.00 | L3MBTL1 (0.41) | L3MBTL1PPARGPPARDPPARAMEN1 | |
| Maltitol SCHEMBL18744690 | 1.00 | L3MBTL1 (0.41) | L3MBTL1PPARGPPARDPPARAMEN1 | |
| Maltitol SCHEMBL13912565 | 1.00 | L3MBTL1 (0.41) | L3MBTL1PPARGPPARDPPARAMEN1 | |
| Maltitol SCHEMBL21947405 | 1.00 | L3MBTL1 (0.41) | L3MBTL1PPARGPPARDPPARAMEN1 | |
| Maltitol SCHEMBL21947406 | 1.00 | L3MBTL1 (0.41) | L3MBTL1PPARGPPARDPPARAMEN1 | |
| Maltitol SCHEMBL22516409 | 1.00 | L3MBTL1 (0.41) | L3MBTL1PPARGPPARDPPARAMEN1 | |
| Maltitol SCHEMBL16153886 | 1.00 | L3MBTL1 (0.41) | L3MBTL1PPARGPPARDPPARAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017024033-A1 | COMPOSITIONS AND KITS FOR VAPOR PHASE DELIVERY OF ACTIVE COMPOUNDS, METHODS OF MAKING AND USING SAME | ATMOVITA, LLC (US) | 2017-02-09 | — | — | WO | claimed |
| JP-7304699-A | — | — | None | — | — | JP | disclosed |
| WO-2025057207-A1 | LAXATIVE COMPOSITIONS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2025-03-20 | — | — | WO | disclosed |
| CN-114901901-B | Fabric spray | 联合利华知识产权控股有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-12023363-B2 | Natural product compositions for treating or managing symptoms of ADD, ADHD, anxiety, and depression | KLELE LUKE (US) | 2024-07-02 | — | — | US | disclosed |
| EP-4324465-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF A MICROBIAL INFECTION IN THE UROGENITAL SYSTEM | Gedea Biotech AB (SE) | 2024-02-21 | — | — | EP | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| CN-111936148-B | Lactitol and oral pharmaceutical dosage form for non-alcoholic fatty liver disease | 瓦伦塔有限责任公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-115836149-A | Fabric spray | 联合利华知识产权控股有限公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2018217769-A1 | PROCESSES FOR PRODUCING LACTITOL GRANULATES AND GRANULATES PRODUCED THEREBY | PARTICLE DYNAMICS INTERNATIONAL, LLC (US) | 2018-11-29 | — | — | WO | disclosed |
| EP-3086796-B1 | PREBIOTIC ORAL CARE METHODS USING A SACCHARIDE | COLGATE PALMOLIVE CO (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-2761020-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2018-06-13 | — | — | EP | disclosed |
| US-20170035011-A1 | METHODS OF IMPROVING GERMINATION OF PLANT EMBRYOS | WEYERHAEUSER NR COMPANY | 2017-02-09 | — | — | US | disclosed |
| US-20160317414-A1 | PREBIOTIC ORAL CARE METHODS USING A SACCHARIDE | COLGATE-PALMOLIVE COMPANY (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160081336-A1 | MEDIUM WITH A PLANT NON-METABOLIZABLE SUGAR FOR IMPROVING SEED GERMINATION | WEYERHAEUSER NR COMPANY (US) | 2016-03-24 | — | — | US | disclosed |
| EP-2761000-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-20110294864-A1 | AQUEOUS COACERVATE COMPOSITIONS SUITABLE FOR MAKING POWDERS AND WATER-SOLUBLE FORMULATIONS OF BIOLOGICALLY-ACTIVE AGENTS | UNIVERSITEIT GENT (BE) | 2011-12-01 | — | — | US | disclosed |
| WO-2010081815-A1 | AQUEOUS COACERVATE COMPOSITION COMPRISING POORLY WATER-SOLUBLE BIOLOGICALLY-ACTIVE AGENTS | UNIVERSITEIT GENT (BE) | 2010-07-22 | — | — | WO | disclosed |
| JP-H07304699-A | HYDROGENATION OF SUGARS | BAYER AG | 1995-11-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081336-A1 | MEDIUM WITH A PLANT NON-METABOLIZABLE SUGAR FOR IMPROVING SEED GERMINATION | NEFM, MGAM, NANS | L3MBTL1 3696/4885PPARG 2430/4885PPARD 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.